CMPX
Compass Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.11 EPS
Last earnings +0.5% on 2026-05-05
$2.08
▲ +0.48%$2.08▼ -18.11%
over 1Y
L $1.67EODHDH $6.69
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.5%
1W-1.0%
1M-8.4%
3M-60.1%
YTD-59.8%
1Y-18.1%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 20 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.12x); but revenue fell -100.0% YoY.
Revenue (FY2025) $0.00 · FY2025
Compass Therapeutics, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -33.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $850K | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M |
| Net income | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| Diluted EPS | -$1.31 | — | — | — | — |
| Net margin | — | — | — | -5808.8% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$344M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-17.8%
FCF yield-13.1%
Quality & risk
ROIC (est.)-29.2%
Free cash flow-$49.2M
Total debt$0.00
Net cash$30.6M
Altman Z-Score7.09 safe
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+30.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-222026-06-23open ↗8-KPeriod ending 2026-06-102026-06-11open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-05open ↗8-KPeriod ending 2026-05-052026-05-05open ↗4/APeriod ending 2026-04-292026-04-30open ↗4/APeriod ending 2026-04-292026-04-30open ↗4Period ending 2026-04-292026-04-29open ↗4Period ending 2026-04-292026-04-29open ↗ARSPeriod ending 2025-12-312026-04-29open ↗DEFA14AFiling2026-04-29open ↗DEF 14APeriod ending 2026-06-102026-04-29open ↗
Frequently asked
- Is Compass Therapeutics, Inc. (CMPX) a buy?
- CMPX currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.12x); but revenue fell -100.0% YoY.
- What is Compass Therapeutics, Inc.'s quality score?
- CMPX scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001738021, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 6:00:11 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.